ATE506456T1 - Verfahren zur behandlung von lentivirusinfektionen - Google Patents

Verfahren zur behandlung von lentivirusinfektionen

Info

Publication number
ATE506456T1
ATE506456T1 AT04776444T AT04776444T ATE506456T1 AT E506456 T1 ATE506456 T1 AT E506456T1 AT 04776444 T AT04776444 T AT 04776444T AT 04776444 T AT04776444 T AT 04776444T AT E506456 T1 ATE506456 T1 AT E506456T1
Authority
AT
Austria
Prior art keywords
present
provides methods
lentivirus infections
treating
identifying
Prior art date
Application number
AT04776444T
Other languages
English (en)
Inventor
Warner Greene
Kimberly Stopak
Noronha Carlos De
Ya-Lin Chiu
Vanessa Soros
Wesley Yonemoto
Original Assignee
David Gladstone Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34068095&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE506456(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by David Gladstone Inst filed Critical David Gladstone Inst
Application granted granted Critical
Publication of ATE506456T1 publication Critical patent/ATE506456T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/702—Specific hybridization probes for retroviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
AT04776444T 2003-06-10 2004-06-09 Verfahren zur behandlung von lentivirusinfektionen ATE506456T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US47754903P 2003-06-10 2003-06-10
US50573803P 2003-09-24 2003-09-24
PCT/US2004/018474 WO2005004798A2 (en) 2003-06-10 2004-06-09 Methods for treating lentivirus infections

Publications (1)

Publication Number Publication Date
ATE506456T1 true ATE506456T1 (de) 2011-05-15

Family

ID=34068095

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04776444T ATE506456T1 (de) 2003-06-10 2004-06-09 Verfahren zur behandlung von lentivirusinfektionen

Country Status (8)

Country Link
US (3) US8338180B2 (de)
EP (1) EP1639141B1 (de)
JP (1) JP4653103B2 (de)
AT (1) ATE506456T1 (de)
AU (1) AU2004255564A1 (de)
CA (1) CA2528120A1 (de)
DE (1) DE602004032340D1 (de)
WO (1) WO2005004798A2 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6831099B1 (en) * 1999-05-12 2004-12-14 Yale University Enzyme inhibition
EP1575992A4 (de) * 2002-08-05 2007-02-21 Univ Rochester Chimäre proteine aus proteintransduzierender domäne/deaminase, verwandte verbindungen und deren verwendungen
WO2005047476A2 (en) * 2003-11-10 2005-05-26 Rigel Pharmaceuticals, Inc. Inhibition of retroviral replication through modulation of the host cell ubiquitylation
MY171061A (en) * 2005-11-09 2019-09-24 Onyx Therapeutics Inc Compounds for enzyme inhibition
CA2657213C (en) 2006-06-19 2017-01-03 Proteolix, Inc. Peptide epoxyketones for proteasome inhibition
WO2008025564A2 (en) * 2006-08-31 2008-03-06 Nexigen Gmbh Methods for detecting protein-peptide interactions
US8999317B2 (en) * 2006-11-01 2015-04-07 University Of Rochester Methods and compositions related to the structure and function of APOBEC3G
US20090176202A1 (en) * 2007-03-23 2009-07-09 Rigel Pharmaceuticals, Inc. Methods of Detecting Inhibitors of VIF-Mediated APOBEC3G Degradation and HIV
US8067632B2 (en) * 2007-07-26 2011-11-29 The Board Of Trustees Of The Leland Stanford Junior University Process to produce prostratin and structural or functional analogs thereof
EP2025750B1 (de) 2007-08-13 2011-12-28 Nexigen GmbH Targets und Zusammensetzungen zur therapeutischen Intervention bei HIV-Infektion
KR20170125413A (ko) 2007-10-04 2017-11-14 오닉스 세라퓨틱스, 인크. 결정형 펩티드 에폭시 케톤 프로테아제 저해제 및 아미노산 케토-에폭시드의 합성
US9084762B2 (en) 2008-09-30 2015-07-21 The Regents Of The University Of California T-cell immunogens derived from anti-viral proteins and methods of using same
EP3090737A1 (de) 2008-10-21 2016-11-09 Onyx Therapeutics, Inc. Kombinationstherapie mit peptidepoxyketonen
CA2653011A1 (en) * 2008-12-03 2010-06-03 Apotex Technologies Inc Method and apparatus for packaging and dispensing pharmaceuticals
TWI504598B (zh) 2009-03-20 2015-10-21 Onyx Therapeutics Inc 結晶性三肽環氧酮蛋白酶抑制劑
JP2011115151A (ja) * 2009-11-05 2011-06-16 National Institute Of Advanced Industrial Science & Technology Ａｐｏｂｅｃ３ｇの活性測定方法
US8853147B2 (en) 2009-11-13 2014-10-07 Onyx Therapeutics, Inc. Use of peptide epoxyketones for metastasis suppression
EP2542238B1 (de) 2010-03-01 2015-08-12 Onyx Therapeutics, Inc. Verbindungen zur immunproteasomhemmung
NZ602872A (en) 2010-04-07 2014-05-30 Onyx Therapeutics Inc Crystalline peptide epoxyketone immunoproteasome inhibitor
US20140105921A1 (en) 2012-07-09 2014-04-17 Onyx Therapeutics, Inc. Prodrugs of Peptide Epoxy Ketone Protease Inhibitors
WO2014055944A1 (en) * 2012-10-04 2014-04-10 Oyagen, Inc. Small molecules as anti-hiv agents that disrupt vif self-association and methods of use thereof
WO2014186423A1 (en) * 2013-05-13 2014-11-20 Oyagen, Inc. Combination therapy for treating hiv and aids
WO2014210082A2 (en) * 2013-06-24 2014-12-31 Oyagen, Inc. Camptothecin derivatives as anti-hiv agents and methods of identifying agents that disrupt vif self-association
WO2016164886A1 (en) * 2015-04-09 2016-10-13 Health Research, Inc. Apobec3a cytidine deaminase induced rna editing
EP3313993A4 (de) 2015-06-29 2019-06-19 Regents of the University of Minnesota Anti-apobec3-antikörper und verfahren zur herstellung und verwendung
US20190085405A1 (en) * 2016-03-23 2019-03-21 Regents Of The University Of Minnesota Methods of detecting apobec3 expression and predicting clinical outcomes
CA3047000A1 (en) 2017-01-04 2018-07-12 Oyagen, Inc. Compounds, compositions, and methods for treating human immunodeficiency virus
GB202110391D0 (en) * 2021-07-19 2021-09-01 Tissue Click Ltd A detection kit and methods of detection of infectious agents
WO2023089808A1 (ja) * 2021-11-22 2023-05-25 隆英 河野 ＡＰＯＢＥＣ３Ｇ／Ｖｉｆ結合体形成阻害剤

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5625048A (en) 1994-11-10 1997-04-29 The Regents Of The University Of California Modified green fluorescent proteins
US5958713A (en) 1995-01-31 1999-09-28 Novo Nordisk A/S Method of detecting biologically active substances by using green fluorescent protein
US5830453A (en) * 1995-05-19 1998-11-03 Emory University Use of IL-13 to induce 15-lipoxygenase
US6051227A (en) * 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5968738A (en) 1995-12-06 1999-10-19 The Board Of Trustees Of The Leland Stanford Junior University Two-reporter FACS analysis of mammalian cells using green fluorescent proteins
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
US6020192A (en) 1996-01-18 2000-02-01 University Of Florida Humanized green fluorescent protein genes and methods
US5976796A (en) 1996-10-04 1999-11-02 Loma Linda University Construction and expression of renilla luciferase and green fluorescent protein fusion genes
TW371617B (en) 1996-10-09 1999-10-11 Of Animal And Plant Health Inspection And Quarantine Council Of Agriculture Executive Yuan Bureau Method to transplant GFP into autographa californica multiple nuclear polyhedrosis virus for inflicting pest in an attempt to detect and flow up it existence and to improve life span against UV
JP2002507410A (ja) 1998-03-27 2002-03-12 プロルーム・リミテッド ルシフェラーゼ、蛍光タンパク質、ルシフェラーゼおよび蛍光タンパク質をコードする核酸および、診断、高処理スクリーニングおよび新規アイテムにおけるその使用
US5985577A (en) 1998-10-14 1999-11-16 The Trustees Of Columbia University In The City Of New York Protein conjugates containing multimers of green fluorescent protein
US20030035790A1 (en) * 1999-01-15 2003-02-20 Shu-Hsia Chen Combination therapy for the prevention or treatment of cancer, inflammatory disorders or infectious diseases in a subject
AU2002232447A1 (en) * 2000-11-02 2002-05-15 Immunex Corporation Method of enhancing lymphocyte-mediated immune responses
US20040009951A1 (en) * 2002-06-13 2004-01-15 Malim Michael H DNA deamination mediates innate immunity to (retro)viral infection
EP1575992A4 (de) * 2002-08-05 2007-02-21 Univ Rochester Chimäre proteine aus proteintransduzierender domäne/deaminase, verwandte verbindungen und deren verwendungen
US7220554B2 (en) * 2003-05-23 2007-05-22 Oregon Health And Science University Methods for identifying inhibitors
CA2537798A1 (en) * 2003-09-03 2005-03-17 University Of Rochester Cytidine deaminase activators, deoxycytidine deaminase activators, vif antagonists, and methods of screening for molecules thereof
WO2005047476A2 (en) * 2003-11-10 2005-05-26 Rigel Pharmaceuticals, Inc. Inhibition of retroviral replication through modulation of the host cell ubiquitylation

Also Published As

Publication number Publication date
CA2528120A1 (en) 2005-01-20
DE602004032340D1 (de) 2011-06-01
WO2005004798A2 (en) 2005-01-20
US20050053977A1 (en) 2005-03-10
US7723021B2 (en) 2010-05-25
WO2005004798A3 (en) 2005-10-20
US20070212756A1 (en) 2007-09-13
EP1639141B1 (de) 2011-04-20
US20070134653A1 (en) 2007-06-14
JP2007502624A (ja) 2007-02-15
EP1639141A4 (de) 2007-05-02
JP4653103B2 (ja) 2011-03-16
US8338180B2 (en) 2012-12-25
EP1639141A2 (de) 2006-03-29
AU2004255564A1 (en) 2005-01-20

Similar Documents

Publication Publication Date Title
ATE506456T1 (de) Verfahren zur behandlung von lentivirusinfektionen
CY1115745T1 (el) Συνθεσεις και μεθοδοι για αντιμετωπιση ή προληψη σχετιζομενης με οξαλικα νοσου
ATE411018T1 (de) Verfahren zur behandlung oder verhinderung von vaskulärer entzündung mit sterol-absorbierungs- inhibitor(en)
ATE279181T1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
DE69915033D1 (de) Verfahren zur keimungshemmende behandlung von knollen und zwiebeln mit eugenol und/oder isoeugenol
ATE453653T1 (de) Platinkomplexe zur behandlung von tumoren
DE602005019874D1 (de) Für die behandlung von thrombotischen leiden geeignete harnstoffantagonisten des p2y1-rezeptors
ATE490778T1 (de) Verwendung von äd-mealaü3-äetvalü4-ciclosporin zur behandlung von hepatitis-c-infektion
CY1117925T1 (el) Μεθοδος αγωγης και βιοπροσδιορισμος που σχετιζεται με παραγοντα αναστολης της μεταναστευσης των μακροφαγων (mif) ως προερχομενο απο την καρδια μυοκαρδιακο κατασταλτικο παραγοντα
EP1595852A4 (de) Verfahren zur behandlung von ammoniakalischen stickstoffenthaltendem wasser
DE60323091D1 (de) Autoimmunerkrankungen und nadph-oxidase-defekte
EP1694342A4 (de) Verfahren zur verwendung von gelsolin zur behandlung oder prävention von bakterieller sepsis
EP1635801A4 (de) Verfahren zur behandlung und prävention von herzarrhythmie
DE602004004883D1 (de) Vegf-antagonisten zur behandlung von diabetes
ATE186121T1 (de) Verfahren zur bestimmung des präthrombotischen status
ATE359816T1 (de) Verfahren zur prävention und behandlung von infektionen mit dem flavivirus bei tieren
ATE402120T1 (de) Verfahren und system zur behandlung von wasser
ATE470453T1 (de) Verfahren zur behandlung von atherosklerose
DE602004010548D1 (de) Verfahren zur behandlung von tierhäuten
DE60325496D1 (de) Verwendung von dihydroimidazolonen zur behandlung von epilepsie bei hunden
DE602004022423D1 (de) Hemmung der s6-kinase-aktivität zur behandlung von insulinresistenz
ATE258064T1 (de) Verwendung von antileukoprotease zur behandlung von endometriose
ATE291425T1 (de) R-eliprodil zur behandlung von glaucoma
ATE545421T1 (de) Pharmazeutisches präparat zur behandlung von parasitären tropenkrankheiten enthaltend diminazen-di-aceturat
ATE349544T1 (de) Verfahren zur herstellung von d-pantothensäure und/oder deren salze als zusatz zu tierfuttermitteln

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties